Skip to content
Licensed Unlicensed Requires Authentication Published by De Gruyter September 21, 2011

Sensitive immunoassays for the autoantibodies reacting against citrullinated carboxy-terminal telopeptides of type I and type II collagens in patients with rheumatoid arthritis

Marja-Kaisa Koivula , Jarmo Ramberg , Sari Åman , Anna Karjalainen , Markku Hakala and Juha Risteli

Abstract

We developed sensitive assay methods for autoantibodies recognizing the citrullinated synthetic peptides derived from type I and type II collagens in patients with rheumatoid arthritis (RA). These peptides were tested with the chemiluminescence method (Nichols Advantage® System). In 44 RA patients out of 120, the sera showed increased binding of citrullinated synthetic C-telopeptide derived from the α1 chain of type I collagen (p=0.003 compared to controls). For a corresponding C-telopeptide pair from the α1 chain of type II collagen, 35 patient sera bound the citrullinated peptide more strongly than the arginine peptide, but the difference compared to the controls was not significant (p=0.074). Correlation between the two carboxy-telopeptides was r=0.473 (p<0.001). The anti-CCP assay (antibodies against citrullinated filaggrin sequence-derived peptides) was positive in 59% of our RA patients. There was no relationship between the anti-CCP results and the antibodies against collagen C-telopeptides, but both are increased in RA patients. We demonstrated autoantibodies in RA patients that bound citrullinated C-telopeptides derived from type I and type II collagen antigens. The peptide sequences detected (-YYXA and -YMXA) were different from that based on the cyclic filaggrin antigen (-STXG-, where X represents citrulline).


Corresponding author: Juha Risteli, Department of Clinical Chemistry, University of Oulu, PL 5000, 90014 Oulu yliopisto, Finland Fax +358-5-3154451,

References

1. Silman AJ. Epidemiology of rheumatoid arthritis. APMIS 1994; 102:721–8.10.1111/j.1699-0463.1994.tb05226.xSearch in Google Scholar

2. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31:315–24.10.1002/art.1780310302Search in Google Scholar

3. Nienhuis RL, Mandema E. A new serum factor in patients with rheumatoid arthritis; the antiperinuclear factor. Ann Rheum Dis 1964; 23:302–5.10.1136/ard.23.4.302Search in Google Scholar

4. Young BJ, Mallya RK, Leslie RD, Clark CJ, Hamblin TJ. Anti-keratin antibodies in rheumatoid arthritis. Br Med J 1979; 2:97–9.10.1136/bmj.2.6182.97Search in Google Scholar

5. Schellekens GA, de Jong BAW, van den Hoogen FHJ, van de Putte LB, van Venrooij WJ. Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest 1998; 101:273–81.10.1172/JCI1316Search in Google Scholar

6. Girbal-Neuhauser E, Durieux JJ, Arnaud M, Dalbon P, Sebbag M, Vincent C, et al. The epitopes targeted by the rheumatoid arthritis-associated antifilaggrin autoantibodies are posttranslationally generated on various sites of (pro)filaggrin by deimination of arginine residues. J Immunol 1999; 162:585–94.Search in Google Scholar

7. Nissinen R, Paimela L, Julkunen H, Tienari PJ, Leirisalo-Repo M, Palosuo T, et al. Peptidylarginine deiminase, the arginine to citrulline converting enzyme, is frequently recognized by sera of patients with rheumatoid arthritis, systemic lupus erythematosus and primary Sjögren syndrome. Scand J Rheumatol 2003; 32:337–42.10.1080/03009740410004990Search in Google Scholar

8. Schellekens GA, Visser H, de Jond BAW, van den Hoogen FH, Hazes JM, Breedveld FC, et al. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 2000; 43:155–63.10.1002/1529-0131(200001)43:1<155::AID-ANR20>3.0.CO;2-3Search in Google Scholar

9. Koivula M-K, Åman S, Karjalainen A, Hakala M, Risteli J. Are there autoantibodies reacting against citrullinated peptides derived from type I and type II collagens in patients with rheumatoid arthritis? Ann Rheum Dis 2005; 64:1443–50.10.1136/ard.2004.031211Search in Google Scholar

10. Yamada R, Suzuki A, Chang X, Yamamoto K. Citrullinated proteins in rheumatoid arthritis. Front Biosci 2005; 10:54–64.10.2741/1506Search in Google Scholar

11. Eberhardt K, Thorbjorn Jensen L, Horslev-Petersen K, Pettersson H, Lorenzen I, Wollheim F. Serum aminoterminal type III procollagen peptide in early rheumatoid arthritis: relation to disease activity and progression of joint damage. Clin Exp Rheumatol 1990; 8:335–40.Search in Google Scholar

12. Burkhardt H, Sehnert B, Bockermann R, Engström Å, Kalden JR, Holmdahl R. Humoral immune response to citrullinated collagen type II determinants in early rheumatoid arthritis. Eur J Immunol 2005; 35:1643–52.10.1002/eji.200526000Search in Google Scholar

13. Suzuki A, Yamada R, Ohtake-Yamanaka M, Okazaki Y, Sawada T, Yamamoto K. Anti-citrullinated collagen type I antibody is a target of autoimmunity in rheumatoid arthritis. Biochem Biophys Res Commun 2005; 333:418–26.10.1016/j.bbrc.2005.05.137Search in Google Scholar PubMed

14. Lundberg K, Nijenhuis S, Vossenaar ER, Palmblad K, van Venrooij WJ, Klareskog L, et al. Citrullinated proteins have increased immunogenicity and arthritogenicity and their presence in arthritic joints correlates with disease severity. Arthritis Res Ther 2005; 7:R458–67.10.1186/ar1697Search in Google Scholar PubMed PubMed Central

15. Hoffman IE, Peene I, Pottel H, Union A, Hulstaert F, Meheus L, et al. Diagnostic performance and predictive value of rheumatoid factor, anti-citrullinated peptide antibodies, and the HLA shared epitope for diagnosis of rheumatoid arthritis. Clin Chem 2004; 50:261–3.Search in Google Scholar

16. Nijenhuis S, Zendman AJ, Vossenaar ER, Pruijn GJ, van Venrooij WJ. Autoantibodies to citrullinated proteins in rheumatoid arthritis: clinical performance and biochemical aspects of an RA-specific marker. Clin Chem Acta 2004; 350:17–34.10.1016/j.cccn.2004.07.016Search in Google Scholar PubMed

17. Union A, Meheus L, Humbel RL, Conrad K, Steiner G, Moereels H, et al. Identification of citrullinated rheumatoid arthritis-specific epitopes in natural filaggrin relevant for antifilaggrin autoantibody detection by line immunoassay. Arthritis Rheum 2002; 46:1185–95.10.1002/art.10229Search in Google Scholar PubMed

18. Vincent C, Nogueira L, Sebbag M, Chapuy-Regaud S, Arnaud M, Letourneur O, et al. Detection of antibodies to deiminated recombinant rat filaggrin by enzyme-linked immunosorbent assay: a highly effective test for the diagnosis of rheumatoid arthritis. Arthritis Rheum 2002; 46:2051–8.10.1002/art.10436Search in Google Scholar PubMed

19. Nogueira L, Chapuy-Regaud S, Constantin A, Clavel C, Sebbag M, Cantagrel A, et al. Autoantibodies to deiminated fibrinogen are the most efficient serological criterion for early rheumatoid arthritis diagnosis [abstract]. Arthritis Res Ther 2003; 5:S6.10.1186/ar648Search in Google Scholar

20. Masson-Bessiere C, Sebbag M, Girbal-Neuhauser E, Nogueira L, Vincent C, Senshu T, et al. The major synovial targets of the rheumatoid arthritis-specific antifilaggrin autoantibodies are deiminated forms of the α- and β-chains of fibrin. J Immunol 2001; 166:4177–84.10.4049/jimmunol.166.6.4177Search in Google Scholar PubMed

21. Vossenaar ER, Despres N, Lapointe E, van der Heijden A, Lora M, Senshu T, et al. Rheumatoid arthritis specific anti-SA antibodies target citrullinated vimentin. Arthritis Res Ther 2004; 6:R142–50.10.1186/ar1149Search in Google Scholar PubMed PubMed Central

22. Visser H, le Cessie S, Vos K, Breedveld FC, Hazes JM. How to diagnose rheumatoid arthritis early: a prediction model for persistent (erosive) arthritis. Arthritis Rheum 2002; 46:357–65.10.1002/art.10117Search in Google Scholar PubMed

23. Nielen MM, van Schaardenburg D, Reesink HW, van de Stadt RJ, van der Horst-Bruinsma IE, de Koning MH, et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum 2004; 50:380–6.10.1002/art.20018Search in Google Scholar PubMed

Received: 2005-6-16
Accepted: 2005-9-1
Published Online: 2011-9-21
Published in Print: 2005-12-1

©2005 by Walter de Gruyter Berlin New York

Downloaded on 3.12.2022 from frontend.live.degruyter.dgbricks.com/document/doi/10.1515/CCLM.2005.239/html
Scroll Up Arrow